EyePoint Pharmaceuticals (EYPT) to Release Earnings on Wednesday

EyePoint Pharmaceuticals (NASDAQ:EYPT - Get Free Report) is anticipated to post its Q1 2025 quarterly earnings results before the market opens on Wednesday, May 7th. Analysts expect the company to announce earnings of ($0.65) per share and revenue of $8.84 million for the quarter.

EyePoint Pharmaceuticals (NASDAQ:EYPT - Get Free Report) last released its quarterly earnings data on Wednesday, May 7th. The company reported ($0.65) earnings per share for the quarter, meeting the consensus estimate of ($0.65). The company had revenue of $24.50 million for the quarter, compared to the consensus estimate of $8.84 million. EyePoint Pharmaceuticals had a negative return on equity of 43.01% and a negative net margin of 226.57%. On average, analysts expect EyePoint Pharmaceuticals to post $-2 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

EyePoint Pharmaceuticals Stock Performance

Shares of NASDAQ:EYPT traded down $0.03 during midday trading on Wednesday, hitting $6.22. 464,705 shares of the stock were exchanged, compared to its average volume of 840,612. The business's 50-day moving average price is $6.02 and its 200 day moving average price is $7.59. The stock has a market capitalization of $427.94 million, a price-to-earnings ratio of -3.11 and a beta of 1.58. EyePoint Pharmaceuticals has a 12 month low of $3.91 and a 12 month high of $13.99.

Analysts Set New Price Targets

Several analysts recently weighed in on the stock. Chardan Capital reissued a "buy" rating and issued a $33.00 price objective on shares of EyePoint Pharmaceuticals in a research note on Thursday, March 6th. StockNews.com raised EyePoint Pharmaceuticals to a "sell" rating in a research note on Friday, March 14th. HC Wainwright restated a "buy" rating and set a $22.00 price target on shares of EyePoint Pharmaceuticals in a report on Thursday, March 6th. Finally, Citigroup started coverage on shares of EyePoint Pharmaceuticals in a research note on Tuesday, January 7th. They set a "buy" rating and a $33.00 target price for the company. One research analyst has rated the stock with a sell rating and nine have given a buy rating to the company's stock. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $26.63.

About EyePoint Pharmaceuticals

EyePoint Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery.